<< Back to MOTIFvations Blog Home Page

Covid-19 Antibodies
 

June 3, 2020

Development & Characterization of Recombinant Human COVID-19 Antibodies

COVID-19 is one of the biggest public health issues in recent history and it has changed the daily lives of almost everyone on the planet. Many biotechnology and pharmaceutical companies, including Active Motif, have been working around the clock since the novel coronavirus outbreak started in China to try to develop new tools to test for and treat the infection.

In February, Active Motif announced that we were part of a collaboration that led to the first cloning, expression, and characterization of recombinant human antibodies from patients that were infected with coronavirus but mounted an immune response and recovered.

These recombinant human COVID-19 antibodies that were generated using our proprietary AbEpic™ platform are now available to the research community. We are also looking for partners and collaborators to continue the development of these recombinant antibodies for diagnostic and/or therapeutic purposes.

Contact Us for More Information or to Collaborate

What is COVID-19?

COVID-19, which is short for coronavirus disease 2019, is the official name of the respiratory disease caused by infection with the novel coronavirus SARS-CoV-2.

The COVID-19 outbreak began in Wuhan, Hubei Province in China, and now almost every country in the world has confirmed cases. COVID-19 was officially declared a worldwide pandemic on March 11th, 2020.

Common symptoms of COVID-19 include fever, tiredness, and a dry cough. COVID-19 patients can also experience shortness of breath, aches and pains, a sore throat, and in some rare cases, symptoms can also include diarrhea and/or nausea.

Why is it Important to Study this Novel Coronavirus?

The virus that causes COVID-19 was named SARS-CoV-2 because it is a coronavirus that is genetically similar to, yet distinct from, the virus that caused the severe acute respiratory syndrome (SARS) outbreak in 2003.

Studying the details of how this virus replicates and causes the disease will allow scientists and physicians to more rapidly develop fast and accurate methods of detection as well as to deploy therapeutic and vaccine strategies.

For example, learning about the critical aspects of the viral life cycle will help researchers identify the best drug targets and, in some cases, doctors can potentially use treatments that are effective at inhibiting other related viruses in efforts to treat SARS-CoV-2 infections.

How Can Antibodies Help Diagnose or Treat COVID-19?

Like many viruses, the COVID-19 virus attaches to a cell that it is infecting through an interaction between a spike protein on the surface of the viral particle and a receptor protein on the surface of the cell.

Since the spike proteins are on the surface of the viral particles, antibodies that bind very specifically and with high affinity to the spike protein can be used in immunological assays like ELISAs to detect the presence of the virus in biological samples.

Furthermore, the detection of antibodies that are specific for the spike protein in patients is a way to determine if a patient was previously infected with the COVID-19 virus and has recovered due to their immune response.

A team of researchers from Germany, Austria, and Russia recently published a report in the scientific journal Cell and concluded that the receptor for SARS-CoV-2 is a protein called ACE2.

Antibodies that bind to the spike protein and prevent it from interacting with ACE2 can “neutralize” the virus, making it unable to infect more cells and therefore treating or limiting the disease. In many patients, the adaptive immune response will develop antibodies to the spike protein that will control the spread of the virus and prevent the disease from becoming severe. However, in some groups of patients, such as the elderly and individuals with certain pre-existing risk factors like heart disease, asthma or other chronic respiratory diseases, or cancer are more likely to develop more serious disease symptoms without medical treatment.

This process of antibody-mediated virus neutralization can also happen through “passive immunity” which involves giving patients antibodies against the spike protein as a treatment. Passive immunity treatments can be performed by removing the serum from someone that was infected with the virus and generated an effective immune response. However, many potential complications can arise from this approach, including potentially exposing the infected patient with additional viruses, so a better and safer alternative is to use highly characterized and purified recombinant antibodies as the therapeutic molecule.

Development of Recombinant COVID-19 Antibodies

Active Motif is a leading manufacturer and provider of research-grade antibodies. Over the many years that we have been manufacturing antibodies for research use, we have continued to advance antibody generation technology by developing novel and innovative technologies to produce recombinant antibodies.

Immediately after the news of the novel coronavirus outbreak in China, scientists at Active Motif Shanghai (a subsidiary of Active Motif, Inc.) started a collaboration with other researchers at Fudan University and its affiliated Public Health Clinical Center to isolate, clone, express, purify, and characterize antibodies from patients infected with the COVID-19 virus.

A combination of having offices and laboratories close to the initial outbreak site and having the right technology for single-cell antibody screening and recombinant antibody generation allowed Active Motif and our partners to respond rapidly to this public health crisis and be the first group to produce recombinant human COVID-19 antibodies.

Contact Us for More Information or to Collaborate

The AbEpic™ Approach to Generating Recombinant Antibodies

AbEpic is a proprietary platform developed by Active Motif that combines the identification of antigen-specific B cells with high-efficiency cloning of antibody heavy and light chains from those cells to yield fully recombinant antibodies with high target specificity.

The AbEpic platform for antibody development has the following advantages over other approaches:

  1. Improved Specificity: Antibody cross-reactivity is significantly reduced by selective panning to remove B cells lacking the desired specificity.
  2. Scalable Production: The recombinant antibodies that are the end product of this platform can be produced at high-volume manufacturing scales under very tightly controlled and regulated conditions, ensuring high quality and essentially limitless supply of these antibodies.
  3. Complete Flexibility: The variable regions of the antibody heavy and light chains can be cloned into a variety of immunoglobulin expression vectors, providing flexibility for use in different downstream applications, such as in vitro diagnostics or therapeutic applications.

In partnership with our collaborators at Fudan University, Active Motif scientists used the AbEpic platform to successfully perform single-cell analysis of B cells from patients that recovered from COVID-19, cloned and expressed the antibody genes, and purified and characterized the recombinant human antibodies.

The characterization assays have demonstrated that these antibodies bind to the SARS-CoV-2 spike protein with high specificity and sensitivity. They also interfere with the binding interaction between the viral spike protein and the ACE2 receptor, suggesting that they have the ability to block or inhibit infection of the COVID-19 virus. These recombinant COVID-19 antibodies have demonstrated potent neutralizing activity in in vitro infection assays with pseudotyped viruses bearing the SARS-CoV-2 spike glycoprotein.

Manufacturing of these recombinant human COVID-19 antibodies has been scaled up and they are available in up to gram quantities to the scientific community for research and commercial applications.

SARS-CoV-2 Clone 414-1 Antibody Data

Characterization of recombinant COVID-19 antibodies. Several assays were performed to characterize the recombinant human COVID-19 antibodies. The data shown here are from one representative recombinant antibody clone AM001414, Cat. No. 91361.*
A.) SARS-CoV-2 Spike protein (Receptor Binding Domain, RBD) binding assay with recombinant human COVID-19 antibodies. SARS-CoV-2 Spike RBD was coated onto microtiter plates and then incubated with the indicated amount of a recombinant human COVID-19 antibody. Bound antibodies were detected with anti-human antibodies conjugated to horse radish peroxidase (HRP) and the resulting absorbance was measured at 450 nm after adding the HRP substrate. The recombinant COVID-19 antibody bound the Spike protein with high affinity. The EC50 value is indicated. B.) Inhibition of COVID-19 Spike RBD/angiotensin converting enzyme-2 (ACE2) interactions by recombinant human COVID-19 antibodies. Using a similar plate-based assay as described in A.), binding of a constant quantity of recombinant ACE2 (His-tagged) in the presence of increasing concentrations of a recombinant human COVID-19 antibody was performed. The recombinant COVID-19 antibody inhibited the interaction between the SARS-CoV-2 Spike protein and ACE2. Bound ACE2 was detected using anti-His Tag-HRP antibody. The IC50 value is indicated. C.) COVID-19 antibodies are neutralizing antibodies and can inhibit infection. Cell-based infection assays using A549 lung epithelial cell line expressing the ACE2 receptor and pseudotyped SARS-CoV-2 virus bearing the S1 spike protein show strong inhibition of viral infection by the recombinant human COVID-19 antibody. The IC50 value is indicated.

* Details on the development and characterization of Active Motif’s SARS-CoV-2 human recombinant antibody clones are available here: Wan J., et. al. (2020) Cell Reports, 32: 107918, July 21, 2020. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection.

We’re in this Fight Against COVID-19 Together, So Let’s Work Together!

These recombinant antibodies can also be developed further for use in diagnostic applications or therapeutic approaches and Active Motif is looking for partners and collaborators to help take these next steps. Contact us by completing the form below to discuss how we can work together.

More information about these antibodies can be found in the table below. Click the More Info button to see experimental data and additional information for each antibody clone. Please fill out the form below to request more information or to obtain a quote for a bulk order.

Fully Human Recombinant Antibodies

Product Name Cat. No. ELISA Western Blot Neutralization*  
SARS-CoV-2 Spike Antibody (AM009105) 91337     More Info
SARS-CoV-2 Spike Antibody (AM038105) 91339     More Info
SARS-CoV-2 Spike Antibody (AM043105) 91341     More Info
SARS-CoV-2 Spike Antibody (AM004414) 91345   More Info
SARS-CoV-2 Spike Antibody (AM005415) 91347     More Info
SARS-CoV-2 Spike Antibody (AM002414) 91349   More Info
SARS-CoV-2 Spike Antibody (AM006415) 91351     More Info
SARS-CoV-2 Spike Antibody (AM032414) 91359     More Info
SARS-CoV-2 Spike Antibody (AM001414) 91361   More Info
SARS-CoV-2 Spike Antibody (AM015553) 91377     More Info
SARS-CoV-2 Spike Antibody (AM002413) 91379     More Info
SARS-CoV-2 Spike Antibody (AM020553) 91381     More Info
SARS-CoV-2 Spike Antibody (AM005505) 91383     More Info
SARS-CoV-2 Spike IgG/IgM Antibody (AM043105) 91385     More Info
SARS-CoV-2 Spike Antibody (AM017553) 91387     More Info

* Viral neutralization assays were performed in A549 lung epithelial cells expressing the ACE2 receptor with a pseudotyped virus containing the SARS-CoV-2 S1 spike glycoprotein and carrying a luciferase reporter gene.

AbFlex® Recombinant Antibodies

Product Name Cat. No. ELISA  
AbFlex® SARS-CoV-2 Spike Antibody (AM002414) 91363 / 91364 More Info
AbFlex® SARS-CoV-2 Spike Antibody (AM009105) 91365 / 91366 More Info
AbFlex® SARS-CoV-2 Spike Antibody (AM043105) 91367 / 91368 More Info
AbFlex® SARS-CoV-2 Spike Antibody (AM038105) 91371 / 91372 More Info
AbFlex® SARS-CoV-2 Spike Antibody (AM004414) 91373 / 91374 More Info
AbFlex® SARS-CoV-2 Spike Antibody (AM001414) 91375 / 91376 More Info

ELISA Pairs in Sandwich ELISA

For use in a plate-based sandwich ELISA, the following antibodies are recommended for capture (plate-coating) and detection. Note that antibodies recommended for detection are non-conjugated so that a secondary antibody which detects human IgG1 will be required.

Capture Antibody Cat. No.
SARS-CoV-2 Spike Antibody (AM002414) 91349
   
Detection Antibody Cat. No.
SARS-CoV-2 Spike Antibody (AM038105) 91339
Capture Antibody Cat. No.
SARS-CoV-2 Spike Antibody (AM001414) 91361
   
Detection Antibody Cat. No.
SARS-CoV-2 Spike Antibody (AM009105) 91337

Additional SARS-CoV-2 Products

In addition to the recombinant antibodies targeting the SARS-CoV-2 spike S1 protein, we also offer many purified recombinant proteins expressed by the COVID-19 virus. These recombinant SARS-CoV-2 proteins are in stock and ready to ship, and are available in up to 1 mg quantities. Contact us to inquire about bulk orders.

Product Name Cat. No. Size  
Recombinant SARS-CoV-2 NSP1 protein 81314 / 81614 50 μg / 1 mg More Info
Recombinant SARS-CoV-2 NSP7 protein 81315 / 81615 50 μg / 1 mg More Info
Recombinant SARS-CoV-2 NSP8 protein 81316 / 81616 50 μg / 1 mg More Info
Recombinant SARS-CoV-2 NSP10 protein 81317 / 81617 50 μg / 1 mg More Info
Recombinant SARS-CoV-2 NSP16 protein 81318 / 81618 50 μg / 1 mg More Info
Recombinant SARS-CoV-2 NSP10 / NSP16 complex 81319 / 81619 50 μg / 1 mg More Info
Rec. SARS-CoV-2 3C-Like Protease (NSP5), His-Tag 81320 / 81620 50 μg / 1 mg More Info
Rec. SARS-CoV-2 3C-Like Protease (NSP5), GST-Tag 81321 / 81621 50 μg / 1 mg More Info

Please note: The submission form below may not display on all browsers. For best results, we recommend using Chrome or Safari as your web browser. If you are having problems accessing the form, please contact technical support.


We’d love to hear from you! Please contact us at blog@activemotif.com or on Twitter (@activemotif) to share your thoughts and feedback! We’re also looking for science writers to contribute to MOTIFvations, so if you’re an established science communicator or just want to get started, please reach out – there might be a story we can collaborate on!

<< Back to MOTIFvations Blog Home Page